Prostate Cancer - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 1699
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P46CFD7A590EN
Leaflet:

Download PDF Leaflet

Prostate Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer – Pipeline Review, H2 2016, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 91, 98, 4, 231, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 12, 10, 58 and 23 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Prostate Cancer Overview
Therapeutics Development
Prostate Cancer - Therapeutics under Development by Companies
Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Prostate Cancer - Pipeline Products Glance
Prostate Cancer - Products under Development by Companies
Prostate Cancer - Products under Investigation by Universities/Institutes
Prostate Cancer - Companies Involved in Therapeutics Development
Prostate Cancer - Therapeutics Assessment
Drug Profiles
Prostate Cancer - Dormant Projects 1571
Prostate Cancer - Discontinued Products 1619
Prostate Cancer - Product Development Milestones 1629
Appendix 1639

LIST OF TABLES

Number of Products under Development for Prostate Cancer, H2 2016
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Development by Companies, H2 2016 (Contd..8)
Number of Products under Development by Companies, H2 2016 (Contd..9)
Number of Products under Development by Companies, H2 2016 (Contd..10)
Number of Products under Development by Companies, H2 2016 (Contd..11)
Number of Products under Development by Companies, H2 2016 (Contd..12)
Number of Products under Development by Companies, H2 2016 (Contd..13)
Number of Products under Development by Companies, H2 2016 (Contd..14)
Number of Products under Development by Companies, H2 2016 (Contd..15)
Number of Products under Development by Companies, H2 2016 (Contd..16)
Number of Products under Development by Companies, H2 2016 (Contd..17)
Number of Products under Development by Companies, H2 2016 (Contd..18)
Number of Products under Development by Companies, H2 2016 (Contd..19)
Number of Products under Development by Companies, H2 2016 (Contd..20)
Number of Products under Development by Companies, H2 2016 (Contd..21)
Number of Products under Development by Companies, H2 2016 (Contd..22)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Development by Companies, H2 2016 (Contd..10)
Products under Development by Companies, H2 2016 (Contd..11)
Products under Development by Companies, H2 2016 (Contd..12)
Products under Development by Companies, H2 2016 (Contd..13)
Products under Development by Companies, H2 2016 (Contd..14)
Products under Development by Companies, H2 2016 (Contd..15)
Products under Development by Companies, H2 2016 (Contd..16)
Products under Development by Companies, H2 2016 (Contd..17)
Products under Development by Companies, H2 2016 (Contd..18)
Products under Development by Companies, H2 2016 (Contd..19)
Products under Development by Companies, H2 2016 (Contd..20)
Products under Development by Companies, H2 2016 (Contd..21)
Products under Development by Companies, H2 2016 (Contd..22)
Products under Development by Companies, H2 2016 (Contd..23)
Products under Development by Companies, H2 2016 (Contd..24)
Products under Development by Companies, H2 2016 (Contd..25)
Products under Development by Companies, H2 2016 (Contd..26)
Products under Development by Companies, H2 2016 (Contd..27)
Products under Development by Companies, H2 2016 (Contd..28)
Products under Development by Companies, H2 2016 (Contd..29)
Products under Development by Companies, H2 2016 (Contd..30)
Products under Development by Companies, H2 2016 (Contd..31)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6)
Prostate Cancer - Pipeline by 4SC AG, H2 2016
Prostate Cancer - Pipeline by AB Science SA, H2 2016
Prostate Cancer - Pipeline by AbbVie Inc, H2 2016
Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016
Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2016
Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H2 2016
Prostate Cancer - Pipeline by Aduro BioTech Inc, H2 2016
Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
Prostate Cancer - Pipeline by Advantagene Inc, H2 2016
Prostate Cancer - Pipeline by Advaxis Inc, H2 2016
Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016
Prostate Cancer - Pipeline by Aileron Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Akshaya Bio Inc, H2 2016
Prostate Cancer - Pipeline by Alchemia Ltd, H2 2016
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Alissa Pharma, H2 2016
Prostate Cancer - Pipeline by Almac Discovery Ltd, H2 2016
Prostate Cancer - Pipeline by Ambrx Inc, H2 2016
Prostate Cancer - Pipeline by American Gene Technologies International Inc, H2 2016
Prostate Cancer - Pipeline by Amgen Inc, H2 2016
Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016
Prostate Cancer - Pipeline by AndroScience Corp, H2 2016
Prostate Cancer - Pipeline by AnGes MG Inc, H2 2016
Prostate Cancer - Pipeline by AntiCancer Inc, H2 2016
Prostate Cancer - Pipeline by Antigen Express Inc, H2 2016
Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H2 2016
Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
Prostate Cancer - Pipeline by Apcure SAS, H2 2016
Prostate Cancer - Pipeline by Aphios Corp, H2 2016
Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2016
Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by Armour Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Arno Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by ArQule Inc, H2 2016
Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Arvinas Inc, H2 2016
Prostate Cancer - Pipeline by Asana BioSciences LLC, H2 2016
Prostate Cancer - Pipeline by Astellas Pharma Inc, H2 2016
Prostate Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016
Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2016
Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
Prostate Cancer - Pipeline by Aura Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2016
Prostate Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
Prostate Cancer - Pipeline by Bayer AG, H2 2016
Prostate Cancer - Pipeline by BeiGene Ltd, H2 2016
Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016
Prostate Cancer - Pipeline by BHR Pharma LLC, H2 2016
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016
Prostate Cancer - Pipeline by Biotest AG, H2 2016
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Blirt SA, H2 2016
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Prostate Cancer - Pipeline by Camurus AB, H2 2016
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H2 2016
Prostate Cancer - Pipeline by CEL-SCI Corp, H2 2016
Prostate Cancer - Pipeline by Celgene Corp, H2 2016
Prostate Cancer - Pipeline by CellCentric Ltd, H2 2016
Prostate Cancer - Pipeline by Cellceutix Corp, H2 2016
Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by Cellmid Ltd, H2 2016
Prostate Cancer - Pipeline by Celprogen Inc, H2 2016
Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2016
Prostate Cancer - Pipeline by Chiome Bioscience Inc, H2 2016
Prostate Cancer - Pipeline by Clovis Oncology Inc, H2 2016
Prostate Cancer - Pipeline by CohBar Inc, H2 2016
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2016
Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H2 2016
Prostate Cancer - Pipeline by Curevac AG, H2 2016
Prostate Cancer - Pipeline by CytoVac A/S, H2 2016
Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2016
Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H2 2016
Prostate Cancer - Pipeline by DEKK-TEC Inc, H2 2016
Prostate Cancer - Pipeline by DexTech Medical AB, H2 2016
Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by DNJ Pharma Inc, H2 2016
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2016
Prostate Cancer - Pipeline by DormaTarg Inc, H2 2016
Prostate Cancer - Pipeline by Eisai Co Ltd, H2 2016
Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2016
Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2016
Prostate Cancer - Pipeline by EndoCeutics Inc, H2 2016
Prostate Cancer - Pipeline by Endocyte Inc, H2 2016
Prostate Cancer - Pipeline by EntreChem SL, H2 2016
Prostate Cancer - Pipeline by EOS Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H2 2016
Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2016
Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Evgen Pharma Plc, H2 2016
Prostate Cancer - Pipeline by Exonate Ltd, H2 2016
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Prostate Cancer - Pipeline by Ferring International Center SA, H2 2016
Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H2 2016
Prostate Cancer - Pipeline by Fountain Biopharma Inc, H2 2016
Prostate Cancer - Pipeline by Fujifilm Corp, H2 2016
Prostate Cancer - Pipeline by G1 Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H2 2016
Prostate Cancer - Pipeline by Genelux Corp, H2 2016
Prostate Cancer - Pipeline by Genentech Inc, H2 2016
Prostate Cancer - Pipeline by GeneSegues Inc, H2 2016
Prostate Cancer - Pipeline by Genmab A/S, H2 2016
Prostate Cancer - Pipeline by Gilead Sciences Inc, H2 2016
Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2016
Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Prostate Cancer - Pipeline by GlycoMimetics Inc, H2 2016
Prostate Cancer - Pipeline by GP Pharm SA, H2 2016
Prostate Cancer - Pipeline by GTx Inc, H2 2016
Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016
Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2016
Prostate Cancer - Pipeline by Hybrigenics SA, H2 2016
Prostate Cancer - Pipeline by IC-MedTech Inc, H2 2016
Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016
Prostate Cancer - Pipeline by IGF Oncology LLC, H2 2016
Prostate Cancer - Pipeline by Ignyta Inc, H2 2016
Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H2 2016
Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
Prostate Cancer - Pipeline by Immuneed AB, H2 2016
Prostate Cancer - Pipeline by Immunocore Ltd, H2 2016
Prostate Cancer - Pipeline by ImmunoFrontier Inc, H2 2016
Prostate Cancer - Pipeline by Immunomedics Inc, H2 2016
Prostate Cancer - Pipeline by Immupharma Plc, H2 2016
Prostate Cancer - Pipeline by Incanthera Ltd, H2 2016
Prostate Cancer - Pipeline by Incuron LLC, H2 2016
Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H2 2016
Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 287

LIST OF FIGURES

Number of Products under Development for Prostate Cancer, H2 2016
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ureter Cancer - Pipeline Review, H2 2016 US$ 1,700.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2017 US$ 1,700.00 Mar, 2017 · 130 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 1,700.00 Apr, 2014 · 50 pages

Ask Your Question

Prostate Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: